## **CRO** services for Acute Liver Failure

Acute liver failure (ALF) carries a high mortality of approximately 40%, which is caused by vial infections (hepatitis A, B and E), drug allergy or autoimmune hepatitis. ALF exhibits symptoms of severe injury such as destruction of hepatocytes or decrease in liver function due to massive necrosis and inflammation.

**Concanavalin A (ConA)-induced acute liver failure model** is widely used for acute immunemediated hepatitis in contrast to several other models, which is primarily driven by the activation and recruitment of T cells to the liver. The outcome of ALF by ConA is leading to severe liver inflammation, tissue necrosis and terminal organ failure.

**SMC**, a Tokyo-based biotech company known as the leading nonclinical CRO for nonalcoholic steatohepatitis (NASH), also provides pharmacology study service of acute ConA model in mice. Our expertise in inflammation/fibrosis is now experienced in liver failure R&D.





## For more information, please contact us below.

Phone: +81-3-6715-9101 / E-mail: info@smclab.co.jp / Website: www.smclab.co.jp